透析依赖ESRD患者减重手术的现代结局:MBSAQIP数据库分析
基于2015-2020年MBSAQIP数据库,比较透析依赖ESRD与非肾病患者接受LSG或LRYGB的30天结局;经1:4倾向评分匹配后,ESRD患者手术时间和住院时间更长,LSG术后死亡率、ICU入住、输血、再入院、再手术和干预均升高,LRYGB术后ICU入住、再入院和干预升高,但绝对并发症率低,ESRD不应视为减重手术禁忌。
要点
- 透析ESRD患者减重术后并发症绝对风险低,不应视为手术禁忌。
- LSG术后ESRD患者死亡率0.7% vs 0.3%,再入院9.1% vs 4.0%。
- LRYGB术后ESRD患者再入院12.4% vs 6.6%,干预5.2% vs 2.0%。
核心结论
- 减重手术对透析依赖ESRD患者是安全的,有助于其获得肾移植机会。
- 尽管ESRD患者术后并发症发生率高于无肾病患者,但绝对并发症率低,且不增加减重手术特异性并发症。
研究设计与样本
- 回顾性分析2015-2020年MBSAQIP数据库,纳入18-80岁接受LSG或LRYGB的患者。
- 采用1:4倾向评分匹配(基于20项术前特征)比较透析依赖ESRD患者与无肾病患者,评估30天术后结局。
主要发现
- LSG队列匹配后ESRD组2137例 vs 无肾病组8495例;LRYGB队列匹配后ESRD组443例 vs 无肾病组1769例。
- LSG术后ESRD组手术时间82.37±40.42 vs 73.62±38.65分钟(P<0.001),住院时间2.22±3.01 vs 1.67±1.90天(P<0.001)。
- LRYGB术后ESRD组手术时间129.13±63.20 vs 118.72±54.16分钟(P=0.002),住院时间2.53±1.74 vs 2.00±1.68天(P<0.001)。
- LSG术后ESRD组死亡率0.7% vs 0.3%(P=0.019),非计划ICU入住3.1% vs 1.3%(P<0.001),输血2.3% vs 0.8%(P=0.001),再入院9.1% vs 4.0%(P<0.001),再手术3.4% vs 1.2%(P<0.001),干预2.3% vs 1.0%(P=0.006)。
- LRYGB术后ESRD组非计划ICU入住3.8% vs 1.4%(P=0.027),再入院12.4% vs 6.6%(P=0.011),干预5.2% vs 2.0%(P=0.050)。
临床怎么用
- 透析依赖ESRD患者行减重手术前应充分评估,术后加强监测和干预以降低再入院和ICU入住风险。
- LSG和LRYGB均可作为ESRD患者肾移植前减重策略,但需根据并发症谱个体化选择术式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe obesity is a relative contraindication for renal transplantation, therefore bariatric surgery is an important option as a pre-kidney transplant weight loss strategy. However, comparative data regarding postoperative outcomes of laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB) in patients with or without ESRD on dialysis are scarce. METHODS: Patients between 18- and 80-year-old who underwent LSG and RYGB were included. To determine the outcomes of patient who underwent bariatric surgery with ESRD on dialysis, a 1:4 PSM was performed between the patients with ESRD on dialysis and those without renal disease. The PSM analyses in both groups were performed using 20 preoperative characteristics. Then 30-day postoperative outcomes were assessed. RESULTS: The operative time and postoperative-LOS were significantly longer in ESRD patients on dialysis compared to those with no renal disease either for LSG (82.37 ± 40.42 vs. 73.62 ± 38.65; P < 0.001, 2.22 ± 3.01 vs. 1.67 ± 1.90; P < 0.001) or for LRYGB (129.13 ± 63.20 vs. 118.72 ± 54.16; P = 0.002, 2.53 ± 1.74 vs. 2.00 ± 1.68; P < 0.001). In the LSG cohort (2137 vs. 8495 matched cases), patients with ESRD on dialysis showed significant increase in mortality (0.7% vs 0.3%; P = 0.019), unplanned ICU admission (3.1% vs 1.3%; P < 0.001), blood transfusions (2.3% vs 0.8%; P 0.001), readmissions (9.1% vs. 4.0%; P < 0.001), reoperations (3.4% vs. 1.2%; P < 0.001), interventions (2.3% vs. 1.0%; P = 0.006). In the LRYGB group (443 vs. 1769 matched cases), patients with ESRD on dialysis showed a significantly higher need for unplanned ICU admission (3.8% vs. 1.4%; P = 0.027), readmissions (12.4% vs. 6.6%; P = 0.011), and interventions (5.2% vs. 2.0%; P = 0.050). CONCLUSION: Bariatric surgery is a safe procedure for patients with ESRD on dialysis to help them get a kidney transplant. Even though this group experienced a higher incidence of postoperative complications compared to those without kidney disease, the absolute complication rates are low and not associated with bariatric-specific complications. Therefore, ESRD should not be perceived as contraindications to bariatric surgery.
引用
- Alothman S, Cornejo J, Adrales G, et al. Comparative outcomes of bariatric surgery in patients with ESRD on dialysis in the modern era of renal transplantation: analysis using the 2015-2020 MBSAQIP database. Surg Endosc. 2023. PMID: 37400685. doi:10.1007/s00464-023-10200-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。